Compare LIVE & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIVE | MAIA |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 49.3M |
| IPO Year | 1998 | 2022 |
| Metric | LIVE | MAIA |
|---|---|---|
| Price | $13.50 | $1.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.2K | ★ 551.5K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 158.14 | 29.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.25 | $0.87 |
| 52 Week High | $25.88 | $3.19 |
| Indicator | LIVE | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 35.09 | 35.97 |
| Support Level | $13.40 | $1.20 |
| Resistance Level | $18.99 | $1.69 |
| Average True Range (ATR) | 1.18 | 0.21 |
| MACD | -0.61 | -0.05 |
| Stochastic Oscillator | 22.71 | 7.62 |
Live Ventures Inc is a holding company of diversified businesses. It acquires and operates companies with a history of earnings power across five segments: Retail-Entertainment, Retail-Flooring, Flooring Manufacturing, Steel Manufacturing, and Corporate & Other. Retail-Entertainment offers new and pre-owned movies, video games, music, books, comics and collectibles through an integrated buy-sell-trade model. Retail-Flooring is a retailer and installer of flooring, carpeting, and countertops, serving consumers, builders, and contractors. Flooring Manufacturing produces and distributes carpet and hard-surface flooring. Steel Manufacturing engages in steel production and fabrication, generating the majority of revenue. Corporate & Other covers corporate costs and legacy products and services.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.